KOSDAQBiotech & Pharma348150

KoBioLabs

₩3,010▲ 0.50%2026-10-02 close

Market Cap

₩58.1B

Turnover

₩48,326,215

Volume

20,000 shares

Shares out.

19.4M

PER

—

PBR

2.0×

EPS

-₩247

Dividend Yield

0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close

Report overview

Revenue Stalls, Losses Widen, Yet First Licensing Deal Lands

As growth in the WeBiome health-supplement business slowed and the 2025 operating loss widened, KoBioLabs marked a milestone by signing Korea's first microbiome drug licensing deal with Celltrion.

1
2025 consolidated revenue rose only 1.3% year over year to KRW 69.29 billion, while the operating loss widened to KRW 9.65 billion from KRW 6.91 billion a year earlier.
2
In March 2026, the company licensed out three bowel-disease drug candidates (KC84, KBL382, KBL385) to Celltrion in a deal worth up to KRW 205.2 billion, including a KRW 1 billion upfront payment.
3
Founder Kwang-Pyo Ko moved to the role of Chief Vision Officer while COO Han-Seung Lee was named the new CEO, shifting the company to a professional-management structure.
4
Over the trailing four quarters (Q3 2025-Q2 2026), owners' net income turned positive in Q3 2025 and Q1 2026, but the company posted a sizable net loss again in Q2 2026.
5
The debt ratio climbed from 29.8% in 2022 to 85.2% in 2025, reflecting a steady rise in financial leverage.

Business structure

Founded in 2014 and listed on Kosdaq in November 2020 through the technology-special listing track, KoBioLabs develops microbiome-based new drugs and health supplements. The business is organized around two pillars.

The first is a microbiome drug pipeline ('CUREbiotics') targeting immune, metabolic, and neurological diseases, built on the company's proprietary Smartiome discovery platform.

The second is a probiotics supplement business ('CAREbiotics') run through WeBiome, a subsidiary established in 2022 as a joint venture with Emart, which accounts for the bulk of consolidated revenue.

Indeed, as of the end of the third quarter, product revenue accounted for 99% of total revenue, all from WeBiome's supplement products.

On the drug side, in March 2026 the company signed a licensing agreement with Celltrion for three bowel-disease drug candidates: KoBioLabs entered a license-in agreement with Celltrion for bowel-disease drug candidates (KC84, KBL382, KBL385), with a total deal value of KRW 205.2 billion, comprising a KRW 1 billion upfront payment and KRW 204.2 billion in development, approval, and sales milestones.

This is regarded as the first case in which an open-innovation partnership with a microbiome company translated into an actual pipeline acquisition.

On the governance front, following the March 2026 shareholders' meeting, founder Kwang-Pyo Ko moved to the role of Chief Vision Officer while COO Han-Seung Lee was appointed the new CEO, and the new CEO is also pursuing development of a microbial drug delivery system (mDDS) as a 'second act' for the company.

WeBiome sells its products through Emart's retail network and online channels, and appears to be expanding into customized B2B probiotics ingredient supply as an additional growth avenue.

Earnings trend

Quarterly revenue · Operating profit

₩17.6B-₩2.8B25Q2₩19.3B-₩400M25Q3₩15.1B-₩3B25Q4₩19.2B-₩2.7B26Q1₩21.8B-₩2B26Q2

RevenueOperating profit

Annual revenue · Operating profit

₩11.6B-₩20.3B2022₩33.1B-₩18.5B2023₩68.4B-₩6.9B2024₩69.3B-₩9.7B2025

RevenueOperating profit

Quarterly results · Last 5 quarters
Quarter	Revenue	Operating profit	Op. margin
2025Q2	₩17.6B	-₩2.8B	−15.9%
2025Q3	₩19.3B	-₩400M	−2.2%
2025Q4	₩15.1B	-₩3B	−19.6%
2026Q1	₩19.2B	-₩2.7B	−13.9%
2026Q2	₩21.8B	-₩2B	−9.2%

Annual results
Year	Revenue	Operating profit	Net income (parent)	Op. margin	ROE	Debt-to-equity
2022	₩11.6B	-₩20.3B	-₩21.9B	−174.8%	−28.4%	29.8%
2023	₩33.1B	-₩18.5B	-₩13.9B	−55.7%	−30.8%	85.4%
2024	₩68.4B	-₩6.9B	-₩5.3B	−10.1%	−14.0%	84.0%
2025	₩69.3B	-₩9.7B	-₩6.3B	−13.9%	−19.5%	85.2%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-08-23

Earnings analysis

KoBioLabs' annual revenue surged from KRW 11.61 billion in 2022 to KRW 33.14 billion in 2023 and KRW 68.36 billion in 2024, but growth slowed sharply in 2025, rising just 1.3% year over year to KRW 69.29 billion.

In contrast, the operating loss, which had narrowed from KRW 20.29 billion in 2022 to KRW 18.46 billion in 2023 and KRW 6.91 billion in 2024, widened again to KRW 9.65 billion in 2025, reversing the prior improvement trend.

Net loss attributable to owners similarly shrank from KRW 21.92 billion in 2022 to KRW 5.30 billion in 2024 before widening again to KRW 6.33 billion in 2025. Operating margin improved from -174.8% in 2022 to -10.1% in 2024, then deteriorated slightly to -13.9% in 2025.

On a quarterly basis, owners' net income turned positive in Q3 2025 (revenue KRW 19.26 billion, operating loss KRW 0.42 billion, net income KRW 0.13 billion) and Q1 2026 (revenue KRW 19.22 billion, operating loss KRW 2.67 billion, net income near breakeven), but in Q4 2025 (operating loss KRW 2.96 billion, net loss KRW 1.13 billion) and Q2 2026 (revenue KRW 21.81 billion, operating loss KRW 2.01 billion, net loss KRW 3.80 billion), net losses exceeded operating losses by a wide margin, suggesting non-operating factors weighed on results.

Operating cash flow (CFO), which improved from -KRW 16.56 billion in 2022 to -KRW 4.36 billion in 2024, worsened again to -KRW 5.78 billion in 2025, indicating that cash generation has not kept pace with revenue growth.

Owners' equity fell steadily from KRW 77.32 billion in 2022 to KRW 32.40 billion in 2025, reflecting the cumulative erosion of capital by accumulated losses. The debt ratio also rose from 29.8% in 2022 to 85.2% in 2025, underscoring growing pressure on the capital structure.

Industry analysis

Microbiome therapeutics remain an early-stage drug modality. Microbiome drugs for treating antibiotic-resistant, hard-to-treat infectious diseases won successive US FDA approvals in 2022 and 2023, but no follow-on successes have emerged since.

As a result, many microbiome companies that listed on Kosdaq around the same time as KoBioLabs pivoted to other modalities such as antibodies, while KoBioLabs has remained focused on microbiome since its founding.

In Korea, the Celltrion licensing deal is regarded as the first commercial deal in the microbiome sector domestically, carrying symbolic significance given the industry's limited track record of validated deals.

In the supplement segment, growth in the probiotics market and the collaboration model with a major retailer (Emart-WeBiome) provide a relatively stable revenue base, though this comes with a structural rise in marketing and fee expenses.

Competitively, most domestic microbiome drug developers remain at early clinical stages, and only a handful have had their pipeline value validated through actual licensing or commercialization deals.

Policy support for commercializing microbiome therapeutics continues at the government level, suggesting the regulatory infrastructure is gradually taking shape.

Outlook

Under the Celltrion agreement, Celltrion plans to pursue development of bowel-disease indications including diarrhea-predominant irritable bowel syndrome (IBS-D) and aims to enter proof-of-concept (PoC) studies within the year, making clinical progress a key point to monitor going forward.

Under new CEO Han-Seung Lee, development of a microbial drug delivery system (mDDS) has been positioned as a new growth pillar, opening the door to further partnering opportunities across both the drug pipeline and platform technology.

In the supplement business, WeBiome appears to be expanding beyond its existing B2C channels into customized B2B probiotics ingredient supply, an effort at revenue diversification.

However, the slowdown in revenue growth and the widening operating loss seen in 2025 results suggest that the WeBiome-led top-line growth strategy may be approaching its limits, and profitability improvement could be delayed without follow-on licensing deals in the drug segment.

The company stated that it plans to use the proceeds from this deal to focus on developing follow-on pipeline candidates and has left open the possibility of expanding collaboration into existing joint-research areas such as atopic dermatitis, beyond IBS-D.

How the shift to professional management affects the pace of commercialization and cost discipline also remains to be seen.

Valuation

PER

—

PBR

2.0×

ROE

-15.4%

EPS

-₩247

BPS

₩1,486

Dividend per share

₩0

KoBioLabs remains in a pre-profit phase, making earnings-based valuation metrics difficult to apply meaningfully. The share price relative to net assets has moved within its multi-year trading range, and with no dividend payment history, dividend-related metrics carry little relevance.

The fact that owners' equity has shrunk over several years due to accumulated losses is important context when interpreting book-value-based metrics.

Event-driven news such as the Celltrion licensing deal can add short-term price volatility, so valuation is best assessed alongside pipeline milestone progress rather than earnings metrics alone.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-08-23

Bull factors

First-Ever Korean Microbiome Licensing Success

The March 2026 license agreement covering three bowel-disease candidates with Celltrion is considered the first commercial microbiome licensing deal by a Korean company.

While the upfront payment itself is modest, the involvement of Celltrion—with its global clinical and direct-sales capabilities—represents external validation of the pipeline's value. Management has also left the door open for expanding the collaboration, which could serve as a foundation for further partnering.

WeBiome Provides a Cash-Generating Revenue Base

The health-supplement subsidiary WeBiome more than doubled consolidated revenue through 2024, helping offset a portion of R&D spending on drug development. Through its joint-venture structure with Emart, the company has secured retail distribution, and recent moves suggest an expansion into B2B ingredient supply.

Given that biotech commercialization typically takes time, having a subsidiary with an established revenue base is a positive factor for financial stability.

Shift to Professional Management With a Focus on Commercialization

With founder Kwang-Pyo Ko stepping into the CVO role in March 2026 and former COO Han-Seung Lee named the new CEO, the company is undergoing a management overhaul that broadens its scope from research toward commercialization, manufacturing, and sales.

The new CEO has proposed a microbial drug delivery system (mDDS) as a new growth axis, exploring commercialization potential in platform technology itself, beyond the drug pipeline.

Bear factors

Revenue Growth Slowdown Coincides With Widening Operating Loss

While consolidated revenue more than doubled in 2024, growth slowed sharply to just 1.3% in 2025. Despite this, the operating loss widened from KRW 6.91 billion to KRW 9.65 billion, raising concerns that the WeBiome-led top-line growth strategy may be reaching its limits.

If SG&A expenses continue to outpace revenue growth, the timeline for profitability improvement could be pushed further out.

Shrinking Capital Base and Rising Debt Ratio

Owners' equity has steadily declined from KRW 77.32 billion in 2022 to KRW 32.40 billion in 2025, while the debt ratio rose sharply from 29.8% to 85.2% over the same period.

If accumulated losses continue to erode capital, the need for additional fundraising (such as rights offerings or convertible bond issuance) could grow, which may result in dilution for existing shareholders.

Small Upfront Payment, Long Path to Milestone Realization

While the total value of the Celltrion agreement reaches KRW 205.2 billion, only KRW 1 billion is a guaranteed upfront payment; the remainder is structured as development, approval, and commercialization milestones.

If clinical development does not proceed smoothly, milestone receipt itself becomes uncertain, meaning a substantial amount of time and clinical success is a prerequisite before any meaningful cash inflow that could improve the balance sheet.

Risk factors

Listing Maintenance Requirements

Technology-special-listed companies receive five-year and three-year grace periods, respectively, for the revenue requirement and the pre-tax loss (relative to equity) requirement before facing potential regulatory-issue designation.

KoBioLabs has been cited in media coverage among companies approaching the end of such grace periods.

One report listed KoBioLabs among companies with standalone (non-consolidated) revenue below KRW 3 billion last year, at KRW 2.6 billion, suggesting that while consolidated revenue clears the threshold, standalone revenue and earnings will require ongoing monitoring.

Clinical and Regulatory Risk

Microbiome therapeutics remain an early-stage modality with limited commercial precedent, and unexpected safety or efficacy issues at the clinical stage could delay development or lead to contract adjustments.

The Celltrion agreement is also milestone-based, meaning actual proceeds could fall well short of the deal's maximum stated value depending on clinical outcomes.

Capital-Raising and Dilution Risk

With persistent operating losses and negative operating cash flow (CFO), and owners' equity shrinking year after year, there remains a standing possibility that the company will need to raise external capital to fund drug development and WeBiome's business expansion. Any rights offering or convertible bond issuance could dilute existing shareholders.

What to watch next

Around November 2026
Around the time of the Q3 2026 quarterly report filing, it will be worth checking whether WeBiome's revenue growth rate recovers and how the operating loss trend evolves.
During Q4 2026
This is the timeframe to verify, via disclosures or IR materials, whether Celltrion's stated plan to enter proof-of-concept (PoC) studies for IBS-D and other bowel-disease indications within the year is actually progressing.
Second half of 2026 through early 2027
It is worth monitoring whether additional partnering, patents, or preclinical results emerge for the microbial drug delivery system (mDDS) platform proposed by the new CEO.
Around March 2027
Around the time of the FY2026 business report filing, it will be important to confirm whether the company meets the regulatory-issue designation criteria (revenue and pre-tax loss ratio) now that the revenue-requirement grace period has expired.

Overall view

KoBioLabs has grown its top line through WeBiome's health-supplement sales, but 2025 marked a phase of sharply slowing revenue growth alongside a renewed widening of the operating loss.

At the same time, the March 2026 licensing deal with Celltrion created the first case of commercial validation for a Korean microbiome drug developer, and the company is also exploring new growth avenues such as a professional-management structure and a microbial drug delivery system (mDDS) platform.

However, the upfront payment itself is small, with the remainder tied to clinical-success-linked milestones, limiting the near-term financial impact. Shrinking owners' equity, a rising debt ratio, and uncertainty around listing-maintenance requirements remain financial-structure concerns.

Going forward, the pace of WeBiome's revenue recovery, clinical progress on the Celltrion pipeline, and the new management's cost-management performance will all need to be confirmed to gauge the direction of earnings improvement.

Sources

Korea Exchange (KRX) — Prices · Market Cap · Volume
FSS electronic disclosure system (DART) — Financial statements · Dividend filings

Show 18 more articles and sources

Report written 2026-09-05 · Data as of 2026-09-04

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.